By Jacob Ahlstrom | Posted - Aug 1st, 2020

 

 

 

 

Uncovering the Benefits of Riluzole for ALS Patients

Riluzole is the only FDA-approved drug therapy for ALS patients. The American Academy of Neurology recommends that Riluzole should be offered to all patients to slow the progression of ALS. Early clinical trials show that it improves life expectancy by 2-3 months on average, but a recent paper uncovers longer efficacy of this early study.  

Originally, the clinical trial for Riluzole did not include patients that were in the first stages of ALS onset. Excluding this data dramatical decreased the average life expectancy for ALS patients using Riluzole therapy.  

The authors of the paper were able to look at data from other studies to get a broader patient population. A broader patient population allows for more precise results because there is more diversity in the larger group. Because patients in the first stages of ALS were not included in the original clinical trials the results are misleading because they do not represent the whole ALS population.  

To fix this, researchers collected data from 15 different studies. Using this data, they show that the median life expectancy is a 6 to 19 month increase when parents start using Riluzole in the initial stages of disease onset. They also found beneficial evidence for both early and prolonged Riluzole therapy in ALS patients.  

“Median survival was 46 months for patients treated with Riluzole for 90% of disease duration compared with 15 months for patients who were treated for <90% of disease duration.” 

One study shows that patients who started long-term treatment with Riluzole in the first stages of ALS onset stayed in the early stages a lot longer than those who started treatment in later stages. Another study shows that median survival was 46 months (about 4 years) for patients treated with Riluzole of 90% of disease duration compared to a 15-month survival rate for patients treated less that 90% of their disease duration.  

More research in this field will help us understand exactly how Riluzole therapy is beneficial. It is thought that Riluzole reduces glutamate concentrations outside the cell, but exactly how or why this helps is unknown. Once we better understand the mechanisms of Riluzole (how it interacts with the body) we can create more effective drugs and find better treatments.  

 

 
 

 
Jacob Ahlstrom
About the Author

Jacob Ahlstrom - Jacob is a Neuroscience undergraduate at Brigham Young University. Jacob's interest in researching and writing about ALS is fueled by his hope to make the process easier for everyone else. Over the last year he has worked alongside Seth Christensen to find ways to educate and connect ALS patients.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

MORE ALS CROWD NEWS